Dallas, Texas (PRWEB) June 16, 2015
The new industry analysis report draws attention towards the high unmet medical needs for patients suffering from this syndrome. The Restless leg syndrome is a neurological disease marked by an overwhelming desire to move the legs, thus resulting in significant pain and disturbance of sleep patterns. The analyst says “The drugs marketed for Restless Legs Syndrome (RLS) such as safinamide by Newron Pharmaceuticals appear to reduce the symptoms by novel mechanisms of action. Safinamide's mechanism of action includes potent, selective, and reversible inhibition of MAO-B, without affecting MAO-A and dopamine uptake, thus enhancing dopaminergic function and inhibiting glutamate release. It reduces the degradation of dopamine, thus showing potential activity in the treatment of RLS. Similarly, Serina's drug SER-214 involves a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology. The drug can be connected to the polymer and delivered to target specific receptors.”
The analysts forecast the global Restless Legs Syndrome (RLS) market to grow at a CAGR of 11.46% over the period 2014-2019.
The Global Restless Legs Syndrome Market 2015-2019 report is about 80 pages and provides 30 Exhibits. The complete report is available at http://www.rnrmarketresearch.com/global-restless-legs-syndrome-market-2015-2019-market-report.html. The report provides key information on Pipeline Candidates: Injectafer, Lisuride, Incobotulinumtoxin A, IPX-159, Safinamide, AZ-008 and SER-214.
According to the Global Restless Legs Syndrome Market 2015-2019 report, the unknown etiology of the disease prevents the introduction of drugs that treat the exact cause of the disease. The currently marketed drugs offer only symptomatic relief. In addition, adverse effects such as nervous system disorders, which include sedation, headache, and dizziness; gastrointestinal disorders such as nausea, dry mouth, and flatulence; psychiatric disorders, including depression and decreased libido; metabolism and nutritional disorders, including weight gain and increased appetite; ear and labyrinth disorders resembling vertigo; and other general disorders such as fatigue, irritability, and peripheral edema are associated with the use of these drugs. The adverse effects caused by the drugs has created the need for unmet in the market. Any drug that can provide a complete cure with minimal side effects would experience widespread adoption in the market.
The report covers the present scenario and the growth prospects of the global Restless Legs Syndrome (RLS) market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of Restless Legs Syndrome (RLS).
The following companies are the key players in the global Restless Legs Syndrome (RLS) market: Boehringer Ingelheim, GlaxoSmithKline, UCB and XenoPort.
Purchase a Copy of Global Restless Legs Syndrome Market 2015-2019 Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=392619.
Other Prominent Vendors in the market are: Alexza Pharmaceuticals, Astellas Pharma, Axxonis Pharma, Bayer Healthcare, Impax Pharmaceuticals, Luitpold Pharmaceuticals, Merz Pharmaceuticals, Mundipharma, Newron Pharmaceuticals, Serina Therapeutics and Teva Neuroscience.
Market Driver: Presence of Unmet Need
Market Trend: Rise in Public Awareness
The Global Restless Legs Syndrome Market 2015-2019 report states that the unknown disease etiology is one of the major challenges for vendors in the market.
Other Related Report:
Global Irritable Bowel Syndrome Market 2015-2019 (http://www.rnrmarketresearch.com/global-irritable-bowel-syndrome-market-2015-2019-market-report.html): The analysts forecast the Global Irritable Bowel Syndrome market to grow at a CAGR of 14.04 percent over the period 2014-2019.
The one major trend upcoming in this market is an increase in public awareness about irritable bowel syndrome, which is expected to increase the number of treatment-seeking patients, thereby increasing the consumption of medications. Growing public awareness increases the number of treatment-seeking patients, thereby leading to increased consumption of approved medications.
The report recognizes the following companies as the key players in the Global Irritable Bowel Syndrome Market: Actavis plc, Astellas Pharma Inc., Nestlé SA and Takeda Pharmaceutical Co. Ltd.
Other Prominent Vendors in the market are: Abbott, Alba Therapeutics, Alfa Wassermann, Alizyme, Almirall, AltheRx Pharmaceuticals, Ardelyx, AstraZeneca, Bayer, Bristol-Myers Squibb, Sumitomo Dainippon Pharma, Dong-A Socio Holdings, Drais Pharmaceuticals, Dynogen, gIcare Pharma, GlaxoSmithKline, Hanmi Pharmaceuticals, ImmusanT, Ironwood Pharmaceuticals, Janssen, Lexicon Pharmaceuticals, Menarini, MicroDose Therapeutx, Norgine, Novartis, Ocera Therapeutics, Ono Pharmaceutical, Par Pharmaceutical, Pfizer, Pharmos, Protagonist Therapeutics, RaQualia Pharma, Rottapharm, Salix, Seldar Pharma, Shire, SK Chemicals, SOFAR, Synergy Pharmaceuticals, Synthetic Biologics, Tioga Pharmaceuticals, Tsumura and Yuhan.
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.